Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is expected to experience financial growth with the potential approval of Jemperli for colorectal cancer and their partnership with Tesaro and GSK. However, a legal dispute with GSK may impact their development and commercialization plans for Jemperli. The company's other drug, imsidolimab, is also in development and expected to contribute to financial growth. Overall, AnaptysBio appears to be in a strong financial position and has potential for success in the pharmaceutical industry.

Bears say

AnaptysBio is a biotechnology company that has seen impressive growth with its rheumatoid arthritis drug, Jemperli, but there are multiple risks in the biotechnology sector including clinical, regulatory, and commercial risks, as well as a need for significant capital. Furthermore, there is an ongoing dispute with GSK/Tesaro over royalties for Jemperli, leading to potential delays in approval and uptake for the drug. The company also has a potential revenue inflection point with its other drug, imsidolimab, but ongoing litigation and regulatory risks could impede future growth.

AnaptysBio (ANAB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 11 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.